Ruthenium-106 Plaque Radiotherapy for Treatment of Uveal Malignant Melanoma: 15 years’ Experience in Tertiary Referral Hospital in Iran
- سال انتشار: 1397
- محل انتشار: بیست و هشتمین کنگره سالیانه انجمن چشم پزشکی ایران
- کد COI اختصاصی: ACSOMED28_176
- زبان مقاله: انگلیسی
- تعداد مشاهده: 381
نویسندگان
Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
چکیده
Purpose: To report the outcome of the Ruthenium-106 eye plaque brachytherapy in patients with uveal malignant melanoma over 15 years in tertiary referral hospital In Iran.Methods: In this retrospective study, the charts of all patients with the diagnosis of uveal malignant melanoma who underwent Ruthenium-106 plaque brachytherapy from 2002 to 2017 were reviewed. All patients had to have at least 6 months of follow up. Clinical features, brachytherapy parameters, outcomes and complications were evaluated.Results: Two hundred and ninety four patients were included. Of them 130 (44.2%) were male. Mean age of patients was 52.14 ± 14.67 years (range 15 to 86). The location of the tumors was choroid in 215 (73.1 %), ciliochoroid in 38 (12.9 %), iridociliary in 31 (10.5 %), iridiociliochoroid in 6 (2 %) and ciliary body in 4 (1.4 %) of the cases. Mean follow up duration was 29.50 ± 19.66 months (range 6 to 80). Mean radiation time was 128.19 ± 73.81 hours. Mean apex dose and mean scleral dose were 8683.00 ± 2167.86 cGy, and 75757.44 ± 44237.08 cGy respectively. The most frequent used plaque type was CCB in 40 (13 %) of cases. The tumor thickness 5.62 ± 2.30 mm in baseline decreased to 3.36 ± 1.94 mm in last follow up. (P< 0.001). The mean preoperative visual acuity was 0.67 LogMAR which increased to 1.01 LogmMAR at last visit. (P< 0.001). Final globe survival was94%. Tumor recurrence was occurred in 29 (9%) of Patients. Second plaque brachytherapy was performed in 10 (3%) and enucleation was done in 18 (6%) of the cases. Adjuvant Transpupillary thermotherapy (TTT) and cataract surgery was performed in 35.6 % and 26.7 % of patients, respectively. Conclusion: Ruthenium-106 plaque radiotherapy is an effective and safe method of treatment for choroidal malignant melanomaکلیدواژه ها
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.